The Clinton Health Access Initiative, Inc. (CHAI) is a global health organization committed to saving lives and reducing the burden of disease in low-and middle-income countries, while strengthening the capabilities of governments and the private sector in those countries to create and sustain high-quality health systems that can succeed without our assistance. For more information, please visit: http://www.clintonhealthaccess.org
Overview of CHAI’s Global Vaccines Program
To ensure all children have access to effective and affordable immunization, addressing the main causes of child mortality, CHAI’s Vaccines Markets Team works with vaccine manufacturers, Gavi and other global stakeholders to improve availability, affordability and diversity of supply for existing and future Gavi vaccines. In doing this, CHAI is applying the techniques it has used successfully to improve access to HIV/AIDS and malaria treatment: improving market demand transparency for individual suppliers, and working closely with these suppliers to optimize their commercial, costing and pricing strategies in low and middle income markets, to ensure availability of vaccines, keep prices in these markets affordable, yet commercially sustainable.
In addition, CHAI’s vaccines markets team is working with suppliers, global partners and investors to accelerate the development of novel, high-impact vaccines such as COVID 19, TB, HIV, and others. Also, CHAI is supporting Gavi and other stakeholders to improve access to vaccines for non-Gavi and former-Gavi middle income countries, through policy as well as supplier and country guidance on vaccine access and procurement. Close collaboration with CHAI’s country teams and global vaccine delivery team is critical along our areas of work.
Since 2011, CHAI has worked in this field and has negotiated price reductions for major vaccines. For example, earlier work has resulted in a reduction in the price of rotavirus vaccine by two-thirds, resulting in savings of over USD$600M for global donors and governments over 5 years and a reduction in the price of pentavalent vaccine by 45%, generating savings of $150M over 4 years. Some selected news articles about CHAI’s work on access in vaccines and other areas are listed here:
WHO press release, January 2018: https://www.who.int/medicines/news/2017/Bharat-Biotech-TypbarTCV-WHO-PQ-Press-Release-Global-Final.pdf?ua=1
WHO press release, April 2013: http://www.who.int/pmnch/media/news/2013/gavi_pentavalent_price_announcement.pdf
The pandemic context has only reinforced the importance of CHAI Vaccines markets team work, coupling the need to ensure supply security for existing vaccines for which demand and supply dynamics are being disrupted, with the need to accelerate time to market of a suitable COVID vaccine on an unprecedented time frame. CHAI is working closely with many partners towards this goal.